vs
Side-by-side financial comparison of Figure Technology Solutions, Inc. (FIGR) and Prestige Consumer Healthcare Inc. (PBH). Click either name above to swap in a different company.
Prestige Consumer Healthcare Inc. is the larger business by last-quarter revenue ($283.4M vs $156.4M, roughly 1.8× Figure Technology Solutions, Inc.). Figure Technology Solutions, Inc. runs the higher net margin — 57.3% vs 16.5%, a 40.8% gap on every dollar of revenue.
Figure Technology Solutions, Inc. is a financial technology company in Reno, Nevada, United States. Established in 2018, it develops and operates blockchain-based platforms used in lending, capital markets, and asset management.
Prestige Consumer Healthcare Inc. is an American company that markets and distributes over-the-counter healthcare and household cleaning products. It was formed by the merger of Medtech Products, Inc., Prestige Brands International, and the Spic and Span Company in 1996. The company is headquartered in Tarrytown, New York and operates a manufacturing facility in Lynchburg, Virginia.
FIGR vs PBH — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $156.4M | $283.4M |
| Net Profit | $89.6M | $46.7M |
| Gross Margin | — | 55.5% |
| Operating Margin | 33.7% | 29.1% |
| Net Margin | 57.3% | 16.5% |
| Revenue YoY | — | -2.4% |
| Net Profit YoY | — | -23.5% |
| EPS (diluted) | $0.34 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $283.4M | ||
| Q3 25 | $156.4M | $274.1M | ||
| Q2 25 | — | $249.5M | ||
| Q1 25 | — | $296.5M | ||
| Q4 24 | — | $290.3M | ||
| Q3 24 | — | $283.8M | ||
| Q2 24 | — | $267.1M | ||
| Q1 24 | — | $277.0M |
| Q4 25 | — | $46.7M | ||
| Q3 25 | $89.6M | $42.2M | ||
| Q2 25 | — | $47.5M | ||
| Q1 25 | — | $50.1M | ||
| Q4 24 | — | $61.0M | ||
| Q3 24 | — | $54.4M | ||
| Q2 24 | — | $49.1M | ||
| Q1 24 | — | $49.5M |
| Q4 25 | — | 55.5% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | — | 54.7% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | — | 29.1% | ||
| Q3 25 | 33.7% | 29.1% | ||
| Q2 25 | — | 28.8% | ||
| Q1 25 | — | 29.8% | ||
| Q4 24 | — | 31.7% | ||
| Q3 24 | — | 29.7% | ||
| Q2 24 | — | 27.0% | ||
| Q1 24 | — | 29.7% |
| Q4 25 | — | 16.5% | ||
| Q3 25 | 57.3% | 15.4% | ||
| Q2 25 | — | 19.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 21.0% | ||
| Q3 24 | — | 19.2% | ||
| Q2 24 | — | 18.4% | ||
| Q1 24 | — | 17.9% |
| Q4 25 | — | $0.97 | ||
| Q3 25 | $0.34 | $0.86 | ||
| Q2 25 | — | $0.95 | ||
| Q1 25 | — | $1.00 | ||
| Q4 24 | — | $1.22 | ||
| Q3 24 | — | $1.09 | ||
| Q2 24 | — | $0.98 | ||
| Q1 24 | — | $0.98 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $62.4M |
| Total DebtLower is stronger | $466.8M | $1.0B |
| Stockholders' EquityBook value | $1.2B | $1.8B |
| Total Assets | $2.2B | $3.5B |
| Debt / EquityLower = less leverage | 0.40× | 0.56× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $62.4M | ||
| Q3 25 | $1.1B | $119.1M | ||
| Q2 25 | — | $139.5M | ||
| Q1 25 | — | $97.9M | ||
| Q4 24 | — | $50.9M | ||
| Q3 24 | — | $51.5M | ||
| Q2 24 | — | $34.3M | ||
| Q1 24 | — | $46.5M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | $466.8M | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | — | $1.8B | ||
| Q3 25 | $1.2B | $1.8B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.7B |
| Q4 25 | — | $3.5B | ||
| Q3 25 | $2.2B | $3.4B | ||
| Q2 25 | — | $3.4B | ||
| Q1 25 | — | $3.4B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $3.3B | ||
| Q1 24 | — | $3.3B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | 0.40× | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $49.3M | $78.3M |
| Free Cash FlowOCF − Capex | — | $75.3M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 1.1% |
| Cash ConversionOCF / Net Profit | 0.55× | 1.68× |
| TTM Free Cash FlowTrailing 4 quarters | — | $267.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $78.3M | ||
| Q3 25 | $49.3M | $57.5M | ||
| Q2 25 | — | $79.0M | ||
| Q1 25 | — | $61.8M | ||
| Q4 24 | — | $65.1M | ||
| Q3 24 | — | $69.8M | ||
| Q2 24 | — | $54.8M | ||
| Q1 24 | — | $66.9M |
| Q4 25 | — | $75.3M | ||
| Q3 25 | — | $55.4M | ||
| Q2 25 | — | $78.2M | ||
| Q1 25 | — | $58.4M | ||
| Q4 24 | — | $63.5M | ||
| Q3 24 | — | $67.8M | ||
| Q2 24 | — | $53.6M | ||
| Q1 24 | — | $63.8M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 20.2% | ||
| Q2 25 | — | 31.3% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 21.9% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 20.1% | ||
| Q1 24 | — | 23.0% |
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | — | 1.68× | ||
| Q3 25 | 0.55× | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | — | 1.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FIGR
Segment breakdown not available.
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
